Ovarian Neoplasms: Clinical Trials

1,329 trials for Ovarian Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

621 completed, 210 terminated, 174 recruiting, 142 unknown. 1329 Phase 2, 364 Phase 1, 29 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21329Completed 621, Terminated 210, Recruiting 174, Unknown 142, Active not recruiting 90, Withdrawn 46, Not yet recruiting 44, Enrolling by invitation 1, Suspended 1
Phase 1364Completed 126, Terminated 77, Recruiting 75, Active not recruiting 30, Unknown 27, Withdrawn 18, Not yet recruiting 9, Enrolling by invitation 1, Suspended 1
Phase 329Recruiting 9, Completed 8, Unknown 4, Active not recruiting 3, Terminated 3, Not yet recruiting 1, Withdrawn 1

Follow Ovarian Neoplasms: new trials by email Literature Review of Ovarian Neoplasms trials Research Report on Ovarian Neoplasms

Trials (filtered) newest first · largest first

All 1,329 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
losartan, Paclitaxel - Platinum Resistant Ovarian Cancer
Phase 2Not yet recruitingMassachusetts General Hospital272027-02-012026-09-22
PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer
Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingShanghai Gynecologic Oncology Group1302026-12-312026-11-17
Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
Fludarabine, Cyclophosphamide - Ovarian Cancer
Phase 2Not yet recruitingMedical University of South Carolina202026-12-012026-07-22
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
LG00313112 - Ovarian Cancer, Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingLG Chem2502026-12-012026-08-07
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer
Phase 2Not yet recruitingDana-Farber Cancer Institute602026-12-012026-09-21
Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors
QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer
Phase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.5582026-11-152026-11-12
MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer
Mirvetuximab Soravtansine, Suvemcitug - Platinum-Sensitive Recurrent Ovarian Cancer
Phase 2Not yet recruitingTongji Hospital802026-11-102026-11-12
Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management
Treatment De-escalation, Additional Treatment - Co-existent Endometrial and Ovarian Carcinoma, Ovarian Carcinoma
Phase 2Not yet recruitingBritish Columbia Cancer Agency902026-10-302026-11-16
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute532026-10-222026-10-01
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
Phase 1 / Phase 2RecruitingCrescent Biopharma, Inc.2192026-10-212026-11-02
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers
Phase 2 / Phase 3RecruitingGE Healthcare1752026-10-012026-06-17
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer
Phase 2Not yet recruitingKalinski, Pawel, MD, PhD282026-10-012026-10-13
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Trastuzumab Rezetecan (SHR-A1811), Carboplatin, Bevacizumab - Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)
Phase 2Not yet recruitingSun Yat-sen University1762026-09-302026-08-20
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
TJ102 - Ovarian Cancer
Phase 1 / Phase 2RecruitingPhrontline Biopharma1502026-09-292026-11-12
Evaluation of XYA02 in Patients With Advanced Solid Tumors
XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingXYone Therapeutics, Inc1902026-09-172026-09-25
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma
Phase 2RecruitingUniversity of Washington262026-09-162026-11-02
Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer
Phase 2RecruitingTufts Medical Center502026-09-122026-11-10
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor
Phase 1 / Phase 2RecruitingUniversity of Chicago242026-09-092026-10-13
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms
Phase 1 / Phase 2Not yet recruitingAdvenchen Pharmaceuticals, LLC.1382026-09-012026-09-10
Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin
Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingUniversity of Colorado, Denver402026-09-012026-09-11

Showing 20 of 1329. Sign in to see all of them.

Narrower conditions

Fallopian Tube Neoplasms (365)  ·  Carcinoma, Ovarian Epithelial (333)  ·  Breast Neoplasms (160)  ·  Endometrial Neoplasms (136)  ·  Neoplasms (113)  ·  Carcinoma, Non-Small-Cell Lung (100)  ·  Uterine Cervical Neoplasms (100)  ·  Colorectal Neoplasms (97)  ·  Pancreatic Neoplasms (88)  ·  Recurrence (76)  ·  Stomach Neoplasms (76)  ·  Sarcoma (72)  ·  Melanoma (65)  ·  Lung Neoplasms (58)

Broader conditions

Urogenital Diseases (1329)  ·  Female Urogenital Diseases (1328)  ·  Female Urogenital Diseases and Pregnancy Complications (1328)  ·  Genital Diseases (1328)  ·  Gonadal Disorders (1327)  ·  Adnexal Diseases (1325)  ·  Endocrine System Diseases (1325)  ·  Genital Diseases, Female (1322)  ·  Urogenital Neoplasms (1319)  ·  Endocrine Gland Neoplasms (1318)  ·  Genital Neoplasms, Female (1316)  ·  Neoplasms by Site (1316)  ·  Ovarian Diseases (1314)  ·  Neoplasms (1216)  ·  Neoplasms by Histologic Type (553)

Interventions

Carboplatin (202)  ·  Paclitaxel (191)  ·  Bevacizumab (120)  ·  pembrolizumab (72)  ·  Gemcitabine (66)  ·  Cyclophosphamide (56)  ·  liposomal doxorubicin (51)  ·  Cisplatin (50)  ·  olaparib (49)  ·  Topotecan (47)  ·  Docetaxel (37)  ·  niraparib (33)  ·  Nivolumab (29)  ·  Taxes (28)  ·  Filgrastim (27)

Sponsors

National Cancer Institute (NCI) (96)  ·  Gynecologic Oncology Group (36)  ·  Memorial Sloan Kettering Cancer Center (30)  ·  M.D. Anderson Cancer Center (27)  ·  Eli Lilly and Company (19)  ·  AstraZeneca (17)  ·  Dana-Farber Cancer Institute (15)  ·  ARCAGY/ GINECO GROUP (14)  ·  Masonic Cancer Center, University of Minnesota (11)  ·  Mayo Clinic (11)  ·  Fred Hutchinson Cancer Center (10)  ·  Roswell Park Cancer Institute (10)  ·  European Organisation for Research and Treatment of Cancer - EORTC (9)  ·  AGO Study Group (8)  ·  Cancer Research UK (8)

Countries

United States (789)  ·  China (151)  ·  Canada (135)  ·  United Kingdom (122)  ·  Spain (121)  ·  France (98)  ·  Belgium (87)  ·  Italy (85)  ·  Germany (81)  ·  Australia (76)  ·  South Korea (65)  ·  Netherlands (46)  ·  Israel (38)  ·  Japan (37)  ·  Denmark (35)

Top investigators

Amir A Jazaeri (5)  ·  Amit Oza (5)  ·  Emese Zsiros (5)  ·  Paul Sabbatini, MD (5)  ·  Steven A Rosenberg, M.D. (5)  ·  Ursula Matulonis, MD (5)  ·  Amy D. Tiersten, MD (4)

Results publications

PMID 37185961, PMID 35170751, PMID 37407274, PMID 19238149, PMID 23922302, PMID 26961146, PMID 35537408, PMID 41044356, PMID 28935273, PMID 31685558, PMID 33337539, PMID 35397664, PMID 36718018, PMID 37496366, PMID 38816232, PMID 39123210, PMID 39695768, PMID 11705489, PMID 11919245, PMID 12065559, PMID 12181243, PMID 12528778, PMID 12586591, PMID 12694666, PMID 12713990, PMID 12826431, PMID 12957454, PMID 14534883, PMID 14615449, PMID 14645425, PMID 14701774, PMID 14767498, PMID 14970858, PMID 15010069, PMID 15177491, PMID 15581974, PMID 15589582, PMID 15592836, PMID 15659504, PMID 15661234, PMID 15699482, PMID 15721430, PMID 15864277, PMID 15999362, PMID 16014111, PMID 16061871, PMID 16249022, PMID 16314647, PMID 16325893, PMID 16500907

NIH funding

U10CA027469 (34), U10CA180868 (27), 2023 (19), 2008 (10), 2009 (10), 2016 (9), 2025 (8), P30CA008748 (8), 2015 (7), 2017 (7), N01CM62203 (7), P30CA015083 (6), 2018 (5), N01CM62201 (5), N01CM62209 (5)